|
Schirdewan博士的引述的參考文獻:
! O9 P! C5 z/ s1 \! g- d. f4 E! M! Y& o4 B6 ?# M& G
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
" |( g; `( o' N ~9 |9 v
& i! R0 Y" [4 d9 S6 JDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 - V/ Z |" ]/ M
[# `% P0 Z4 F! I* B o( ?Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
$ b6 m+ W$ p E1 `8 w7 r- O( M/ z6 p
1 R" K! |* V: G" _+ e; x& q關於BIOTRONIK SE & Co. KG
3 ^; M9 p v5 W# |& c
5 r: d* R1 C3 }' xBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|